CAJ | 학술논문

目的探讨生物反馈联合药物治疗对慢性前列腺炎/慢性骨盆疼痛综合征(CP/CPPS)患者前列腺液中干扰素γ(INF-γ)及转化生长因子β1(TGF-β1)表达的影响.方法将55例CP/CPPS患者根据美国国立卫生研究院(NIH)前列腺炎分型标准分型后均接受生物反馈治疗20次、每次20 min,同时给予常规药物治疗.治疗前后分别评价NIH慢性前列腺炎症状指数(NIH-CPSI)评分,并采用双抗体夹心酶联免疫吸附试验法测定16例健康男性及各型CP/CPPS患者治疗前后前列腺液中INF-γ、TGF-β1的表达水平.结果 55例CP/CPPS患者NIH-CPSI总分治疗前后分别为(26.36±6.16)分和(10.24±5.18)分,症状程度评分治疗前后分别为(19.59±4.67)分和(7.35±3.46)分,治疗后均较治疗前改善,差异有统计学意义(P＜0.01).CP/CPPSⅢA型及ⅢB型患者治疗前前列腺液中INF-γ、TGF-β1水平均明显高于健康男性[(14.89±7.43)、(13.51 ±5.88)ng/L比(7.56±1.52)ng/L,(8464.41±4604.49)、(7985.19±5068.07)ng/L比(2475.50±973.42)ng/L],差异有统计学意义(P＜0.01)；治疗后前列腺液中INF-γ、TGF-β1水平[(8.63±1.86)、(8.23±1.75)ng/L和(2887.32±926.45)、(2576.50±955.38)ng/L]均较治疗前明显降低,差异有统计学意义(P＜0.01),与健康男性比较差异无统计学意义(P＞0.05).结论生物反馈联合药物治疗CP/CPSS安全、有效,可显著降低其前列腺液中INF-γ及TGF-β1表达.
목적 탐토생물반궤연합약물치료대만성전렬선염/만성골분동통종합정(CP/CPPS)환자전렬선액중간우소γ(INF-γ)급전화생장인자β1(TGF-β1)표체적영향.방법 장55례CP/CPPS환자근거미국국립위생연구원(NIH)전렬선염분형표준분형후균접수생물반궤치료20차、매차20 min,동시급여상규약물치료.치료전후분별평개NIH만성전렬선염증상지수(NIH-CPSI)평분,병채용쌍항체협심매련면역흡부시험법측정16례건강남성급각형CP/CPPS환자치료전후전렬선액중INF-γ、TGF-β1적표체수평.결과 55례CP/CPPS환자NIH-CPSI총분치료전후분별위(26.36±6.16)분화(10.24±5.18)분,증상정도평분치료전후분별위(19.59±4.67)분화(7.35±3.46)분,치료후균교치료전개선,차이유통계학의의(P＜0.01).CP/CPPSⅢA형급ⅢB형환자치료전전렬선액중INF-γ、TGF-β1수평균명현고우건강남성[(14.89±7.43)、(13.51 ±5.88)ng/L비(7.56±1.52)ng/L,(8464.41±4604.49)、(7985.19±5068.07)ng/L비(2475.50±973.42)ng/L],차이유통계학의의(P＜0.01)；치료후전렬선액중INF-γ、TGF-β1수평[(8.63±1.86)、(8.23±1.75)ng/L화(2887.32±926.45)、(2576.50±955.38)ng/L]균교치료전명현강저,차이유통계학의의(P＜0.01),여건강남성비교차이무통계학의의(P＞0.05).결론 생물반궤연합약물치료CP/CPSS안전、유효,가현저강저기전렬선액중INF-γ급TGF-β1표체.
Objective To study the effect of biofeedback combined with drugs therapy on interferon-γ(INF)-γ and transforming growth factor-β1(TGF-β1)in expressed prostatic secretions of patients with chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS).Methods Fifty-five patients who had been diagnosed as CP/CPPS were classified according to U.S.National Institutes of Health(NIH)classification system for prostatitis and received the treatment of biofeedback therapy (20 times and 20 min every time)in addition to the general drugs.The efficacy was evaluated by the NIH chronic prostatitis symptom index(NIH-CPSI)before and after treatment.INF-γ and TGF-β1 levels were measured in expressed prostatic secretions of 55 patients with CP/CPPS and 16 normal controls by double antibody enzyme-linked immune sandwich assay.Results The overall NIH-CPSI scores were(26.36 ± 6.16)scores and(10.24 ± 5.18)scores,and symptom degree scores were(19.59 ± 4.67)scores and (7.35 ± 3.46)scores pre-and post-treatment in 55 patients with CP/CPPS,significant differences of reduces were found compared with pre-treatment(P ＜ 0.01).INF-γ and TGF-β 1 levels in expressed prostatic secretions pre-treatment in CP/CPPS patients with Ⅲ A type and Ⅲ B type were higher than those in normal controls [(14.89 ± 7.43),(13.51 ± 5.88)ng/L vs.(7.56 ± 1.52)ng/L,(8464.41 ± 4604.49),(7985.19 ± 5068.07)ng/L vs.(2475.50 ± 973.42)ng/L],there were significant differences(P ＜ 0.01);which post-treatment were lower than those pre-treatment [(8.63 ± 1.86),(8.23 ± 1.75)ng/L and(2887.32 ±926.45),(2576.50 ± 955.38)ng/L],and there were significant differences(P ＜ 0.01),but there was no significant difference compared with normal controls(P ＞ 0.05).Conclusion Biofeedback combined with drugs therapy in treatment of CP/CPPS is effective and safe.And the expression of INF-γ and TGF-β1 in expressed prostatic secretions can be significantly reduced by this therapy.